Application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis

A steatohepatitis, non-alcoholic technology, applied in the field of medicine, can solve the problems of insufficient clinical treatment methods for NASH, and achieve the effect of reducing liver lipid deposition

Active Publication Date: 2020-01-03
CHINA PHARM UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Technical problem to be solved: The present invention aims at the problem of insufficient clinical treatment methods for NASH at present, and provides CHRNA4 as a target in screening non-alcoholic steatohepatitis therapeutic drugs, preparing non-alcoholic steatohepatitis therapeutic drugs or preparing non-alcoholic steatohepatitis therapeutic drugs. Application of Hepatitis Diagnostic Drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis
  • Application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis
  • Application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] CHRNA4 is a potential therapeutic target for NASH

[0031] 1. Construction of high-fat feeding (HFD) and high-fat high-sugar feeding (HFFD) models: 5-week-old male C57BL / 6J mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were placed in a standard SPF environment (without Special pathogens, kept at a constant temperature of 25°C, with lighting at intervals of 12 hours). At the beginning of modeling, the mice were divided into two groups. One group of mice was fed with high-fat diet (HFD) (high-fat feed was purchased from American Research Diet Company, item number D12492), and the other group of mice were fed with high-fat diet and fructose-containing diet. Water (2.31g fructose / 100mL drinking water) feeding (HFFD), free food intake, after 21 weeks of feeding, mice were dissected, and samples were taken and tested.

[0032] Total RNA extraction and qPCR detection: Take an appropriate amount of the above-mentioned HFD and HFFD model m...

Embodiment 2

[0075] The therapeutic effect of Lobeline Hydrochloride on NASH

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of CHRNA4 in preparation of drugs for treating nonalcoholicity steathopatitis. It is disclosed by a nonalcoholicity steathopatitis (abbreviated as NASH) mice induced by high-fat and high-sugar diets that the CHRNA4 can be used as a potential therapeutic target of the NASH, and the therapeutic effect of the antagonist lobelin hydrochloride of the CHRNA4 on theNASH is proved to provide a new way to treat the NASH.

Description

technical field [0001] The invention belongs to the technical field of medicines, in particular to the application of CHRNA4 in the preparation of medicines for treating nonalcoholic steatohepatitis. Background technique [0002] The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing year by year all over the world, and it has become one of the most common liver diseases in children and adults. Nonalcoholic steatohepatitis (NASH) is a further development of nonalcoholic steatosis of the liver (NAFL), accompanied by liver cell damage and liver inflammation, and can develop into liver fibrosis, cirrhosis, and increased liver cancer and Risk of other liver-related deaths. NASH is becoming the leading cause of liver transplantation, and there is no effective drug yet. Therefore, it is imperative to explore potential therapeutic targets and develop effective drug treatments. [0003] Nicotinic acetylcholine receptors (non-neuronal nicotinic acetylcholine recep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/576A61K45/00A61P1/16
CPCG01N33/6893G01N33/576A61K45/00A61P1/16G01N2333/705
Inventor 王丽蕊高颖生潘楚玥刘俊
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap